Correlation of bioavailable 1,25（OD）2D level with bone mineral density and bone metabolic markers in patients with nephrotic syndrome

doi:10.3969/j.issn.1673-8640.2019.08.009

Abstract

Abstract:

Objective To investigate the correlation between bioavailable 1,25-hydroxyvitamin D [1,25（OH）₂D] level and bone mineral density（BMD） and bone metabolic markers in patients with nephrotic syndrome（NS）. Methods A total of 80 NS patients（NS group） and 60 healthy subjects（healthy control group） with similar sex,age and body mass index（BMI） were enrolled. The data on sex,age,height,weight,blood pressure,smoking history and drinking history of all the subjects were recorded,and BMI was calculated. The BMD,serum creatinine（SCr）,total cholesterol（TC）,triglyceride（TG）,albumin（Alb）,calcium,phosphorus,intact parathyroid hormone（iPTH）,total 1,25（OH）₂D and vitamin D binding protein（DBP） were determined,and bioavailable 1,25（OH）₂D was calculated. Multivariate Logistic regression analysis was used to evaluate the correlations between the indicators and 1,25（OH）₂D levels. Results The systolic blood pressure,serum Alb,Ca,total 1,25（OH）₂D and bioavailable 1,25（OH）₂D levels in NS group were lower than those in healthy control group（P<0.05）,and the diastolic blood pressure and serum TC,TG,phosphorus and iPTH were higher than those in healthy control group（P<0.05）. There was no statistical significance between the 2 groups in smoking history ratio,drinking history ratio,SCr,estimated glomerular filtration rate（eGFR）,serum DBP and BMD （P>0.05）. Total 1,25（OH）₂D and bioavailable 1,25（OH）₂D levels in NS group were positively correlated with BMD,Alb and DBP（P<0.01） and were negatively correlated with iPTH and TC（P<0.01）,and there was no correlation with the other indicators（P>0.05）. Conclusions Low levels of total 1,25（OH）₂D and bioavailable 1,25（OH）₂D in NS group are related to BMD and bone metabolic markers.

Key words: Bioavailable 1, 25-hydroxyvitamin D, Bone mineral density, Bone metabolic marker, Nephrotic syndrome

CLC Number:

R446.1

SUN Liangbo, JING Haining. Correlation of bioavailable 1,25（OD）₂D level with bone mineral density and bone metabolic markers in patients with nephrotic syndrome[J]. Laboratory Medicine, 2019, 34(8): 717-721.

Figures/Tables 2

References 16

[1]	AGGARWAL A,YADAV A K,RAMACHANDRAN R,et al.Bioavailable vitamin D levels are reduced and correlate with bone mineral density and markers of mineral metabolism in adults with nephrotic syndrome[J]. Nephrology(Carlton),2016,21(6):483-489.
[2]	WANG X,SHAPSES S A,AL-HRAISHAWI H.Free and bioavailable 25-hydroxyvitamin D levels in patients with primary hyperparathyroidism[J]. Endocr Pract,2017,23(1):66-71.
[3]	柯文才,武强,顾云霞. 老年2型糖尿病患者骨代谢标志物与骨密度的相关性分析[J]. 检验医学,2017,32(2):86-89.
[4]	BHAN I,POWE C E,BERG A H,et al.Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients[J]. Kidney Int,2012,82(1):84-89.
[5]	中华中医药学会肾病分会. 原发性肾病综合征的诊断、辨证分型及疗效评定(试行方案)[J]. 上海中医药杂志,2006,40(10):51-52.
[6]	GOSWAMI R,SAHA S,SREENIVAS V,et al.Vitamin D-binding protein,vitamin D status and serum bioavailable 25(OH)D of young Asian Indian males working in outdoor and indoor environments[J]. J Bone Miner Metab,2017,35(2):177-184.
[7]	SEELHAMMER T G,MAILE M D,HEUNG M,et al.Kinetic estimated glomerular filtration rate and acute kidney injury in cardiac surgery patients[J]. J Crit Care,2016,31(1):249-254.
[8]	范光磊,栾玉芬,彭鸣亚,等. 骨转换生化指标与原发性肾病综合征并发肾性骨营养不良的相关性研究[J]. 中华核医学与分子影像杂志,2015,35(1):44-47.
[9]	BANERJEE S,BASU S,SEN A,et al.The effect of vitamin D and calcium supplementation in pediatric steroid-sensitive nephrotic syndrome[J]. Pediatr Nephrol,2017,32(11):2063-2070.
[10]	SELEWSKI D T,CHEN A,SHATAT I F,et al.Vitamin D in incident nephrotic syndrome: a midwest pediatric nephrology consortium study[J]. Pediatr Nephrol,2016,31(3):465-472.
[11]	BENNETT M R,PORDAL A,HAFFNER C,et al.Urinary vitamin D-binding protein as a biomarker of steroid-resistant nephrotic syndrome[J]. Biomark Insights,2016,11:1-6.
[12]	SRIKANTH P,CHUN R F,HEWISON M,et al.Associations of total and free 25OHD and 1,25(OH) 2D with serum markers of inflammation in older men[J]. Osteoporos Int,2016,27(7):2291-2300.
[13]	KIM H J,JI M,SONG J,et al.Clinical utility of measurement of vitamin D-binding protein and calculation of bioavailable vitamin D in assessment of vitamin D status[J]. Ann Lab Med,2017,37(1):34-38.
[14]	LI C,CHEN P,DUAN X,et al.Bioavailable 25(OH)D but not total 25(OH)D is an independent determinant for bone mineral density in Chinese postmenopausal women[J]. EBioMedicine,2017,15:184-192.
[15]	LIN Y,HONG C,MIAO Z,et al.Prognostic value of circulating vitamin D binding protein,total,free and bioavailable 25-hydroxy vitamin D in patients with colorectal cancer[J]. Oncotarget,2017,8(25):40214-40221.
[16]	ELOI B M,HORVATH D V,ORTEGA J C,et al.25-Hydroxivitamin D serum concentration,not free and bioavailable vitamin D,is associated with disease activity in systemic lupus erythematosus patients[J]. PLoS One,2017,12(1):e0170323.

组别	例数	收缩压（kPa）	舒张压（kPa）	总1,25（OH）₂D （nmol/L）	生物可利用1,25（OH）₂D（nmol/L）	SCr （mg/L）	TC （mg/L）
NS组	80	15.06±1.15	10.78±0.87	20.56±4.55	1.62±0.52	0.09±0.02	32.11±5.64
正常对照组	60	15.87±1.18	9.94±0.79	30.45±5.02	5.02±1.57	0.10±0.02	17.73±3.06
统计值		3.83	-5.75	8.12	7.44	0.79	-14.52
P值		< 0.01	<0.01	<0.01	<0.01	0.43	<0.01
组别		TG（mg/L）	Alb（g/L）	钙（mg/L）	磷（mg/L）	iPTH（μg/L）	DBP（mg/L）
NS组		26.13±4.54	0.23±0.06	0.81±0.11	0.39±0.06	74.26±13.65	225.62±38.64
正常对照组		14.51±2.09	0.48±0.07	0.91±0.06	0.32±0.05	42.57±10.72	234.12±35.25
统计值		-10.56	5.77	6.78	-7.28	-9.12	1.02
P值		<0.01	<0.01	<0.01	<0.01	<0.01	0.15
组别		尿DBP/Cr比值	BMD （g/cm²）	eGFR [mL/（min·1.73 m²）]	24 h尿蛋白（g/d）	吸烟史 [例（%）]	嗜酒史 [例（%）]
NS组		75.26±18.68	0.80±0.12	98.22±20.54	5.52±2.06	20（25）	13（16.25）
正常对照组		10.57±3.05	0.81±0.13	96.34±21.03		18（30）	10（16.67）
统计值		-18.62	0.47	-0.82		0.43	0.00
P值		<0.01	0.64	0.42		0.51	0.95

组别	例数	收缩压（kPa）	舒张压（kPa）	总1,25（OH）₂D （nmol/L）	生物可利用1,25（OH）₂D（nmol/L）	SCr （mg/L）	TC （mg/L）
NS组	80	15.06±1.15	10.78±0.87	20.56±4.55	1.62±0.52	0.09±0.02	32.11±5.64
正常对照组	60	15.87±1.18	9.94±0.79	30.45±5.02	5.02±1.57	0.10±0.02	17.73±3.06
统计值		3.83	-5.75	8.12	7.44	0.79	-14.52
P值		< 0.01	<0.01	<0.01	<0.01	0.43	<0.01
组别		TG（mg/L）	Alb（g/L）	钙（mg/L）	磷（mg/L）	iPTH（μg/L）	DBP（mg/L）
NS组		26.13±4.54	0.23±0.06	0.81±0.11	0.39±0.06	74.26±13.65	225.62±38.64
正常对照组		14.51±2.09	0.48±0.07	0.91±0.06	0.32±0.05	42.57±10.72	234.12±35.25
统计值		-10.56	5.77	6.78	-7.28	-9.12	1.02
P值		<0.01	<0.01	<0.01	<0.01	<0.01	0.15
组别		尿DBP/Cr比值	BMD （g/cm²）	eGFR [mL/（min·1.73 m²）]	24 h尿蛋白（g/d）	吸烟史 [例（%）]	嗜酒史 [例（%）]
NS组		75.26±18.68	0.80±0.12	98.22±20.54	5.52±2.06	20（25）	13（16.25）
正常对照组		10.57±3.05	0.81±0.13	96.34±21.03		18（30）	10（16.67）
统计值		-18.62	0.47	-0.82		0.43	0.00
P值		<0.01	0.64	0.42		0.51	0.95

项目	SCr	TC	TG	Alb	钙	磷	DBP
总1,25（OH）₂D
r值	0.09	-0.28	-0.20	0.36	0.12	-0.18	0.39
P值	0.71	0.02	0.31	<0.01	0.45	0.41	<0.01
生物可利用1,25（OH）₂D
r值	0.11	-0.30	-0.18	0.41	0.13	-0.19	0.35
P值	0.61	0.01	0.44	<0.01	0.44	0.38	<0.01

项目	SCr	TC	TG	Alb	钙	磷	DBP
总1,25（OH）₂D
r值	0.09	-0.28	-0.20	0.36	0.12	-0.18	0.39
P值	0.71	0.02	0.31	<0.01	0.45	0.41	<0.01
生物可利用1,25（OH）₂D
r值	0.11	-0.30	-0.18	0.41	0.13	-0.19	0.35
P值	0.61	0.01	0.44	<0.01	0.44	0.38	<0.01

Correlation of bioavailable 1,25（OD）₂D level with bone mineral density and bone metabolic markers in patients with nephrotic syndrome

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 16

Related Articles 15

Recommended Articles

Metrics

[1]	TANG Qingqin, QIAO Longwei, YIN Jingping, ZHANG Sheng, FENG Bin, LIANG Yuting. Correlation of peripheral blood monocyte count and serum anti-phospholipase A2 receptor antibody in patients with nephrotic syndrome [J]. Laboratory Medicine, 2023, 38(7): 647-652.
[2]	LIU Yang, GENG Kunjing, LI Hongjiang, SHI Haoxi, CHEN Sisi. Relationship of 25（OH）D₃ and liver inflammatory stage with the efficacy of antiviral therapy [J]. Laboratory Medicine, 2022, 37(7): 628-631.
[3]	ZHANG Zhibin, YANG Wanyong, RUAN Fuwang, WEN Qinghui. Roles of total IgE,sIgE and 25（OH）D in the evaluation of infant atopic dermatitis [J]. Laboratory Medicine, 2022, 37(3): 217-220.
[4]	ZHAO Xiaomin, JIANG Xiaoyu, SHAN Kaili, SHAN Tieying, LIU Xiuzhen. Roles of Flt-3L，TF and 25（OH）D in iron deficiency anemia among infants and children [J]. Laboratory Medicine, 2022, 37(11): 1039-1043.
[5]	LI Dingfu, HUANG Jian, CAI Meiling, WANG Lizhen, JIAN Kaigan, YANG Feifei. Relationship between serum 25（OH）D and disease control in children with allergic rhinitis-asthma syndrome [J]. Laboratory Medicine, 2022, 37(1): 32-35.
[6]	ZHAO Xueling, ZHENG Xin, XU Huamei, SHI Hongyao. Correlation between serum 25（OH）D,specific IgE and VAS score in children with allergic rhinitis [J]. Laboratory Medicine, 2021, 36(6): 615-617.
[7]	LI Bingling, CHENG Yating, ZHAO Beibei, SHE Xuhui, DONG Heng, YU Mujun. Evaluation of surrogate matrices for serum 25-hydroxyvitamin D calibrators by LC-MS/MS [J]. Laboratory Medicine, 2021, 36(2): 213-218.
[8]	FANG Huiling, GE Danhong, ZHU Yuqing, ZHU Lingfeng, ZHAO Xiaojun, CHEN Ziqi, WANG Zimeng. Analysis on the external quality assessment results for 25-hydroxyvitamin D of Shanghai from 2015 to 2019 [J]. Laboratory Medicine, 2021, 36(2): 219-224.
[9]	CHEN Gang, WANG Jing, DENG Qiang, CHEN Xi, HU Dong, ZHUANG Lidong. Correlation and risk assessment of serum 25（OH）D level and multiple thyroid function indicators in patients with thyroid cancer before operation [J]. Laboratory Medicine, 2020, 35(9): 885-888.
[10]	ZHANG Sujie, JU Yi, LI Qing, SUN Hewei, FENG Xueqing, JIN Zhonggan, LI Shuijun, LI Yujie, LI Jinrong. Analysis of serum 25-hydroxyvitamin D levels in healthy subjects [J]. Laboratory Medicine, 2020, 35(10): 1028-1031.
[11]	YANG Juan, XU Jin. Changes of serum hepcidin levels in postmenopausal women with osteoporosis [J]. Laboratory Medicine, 2019, 34(1): 23-27.
[12]	LIN Xiangquan, CHEN Hong. Roles of serum 25-hydroxyvitamin D and bone mineral density in children with obesity [J]. Laboratory Medicine, 2018, 33(8): 669-673.
[13]	LUO Qingxin, CHEN Kaiting, LAN Yanling, MO Xin, CHEN Jiaqiang. Additive effect of serum 25-hydroxyvitamin D₃ in the treatment of depression [J]. Laboratory Medicine, 2018, 33(6): 491-494.
[14]	LI Yaju, CHEN Kun, GUAN Ming. Roles of 25-hydroxyvitamin D levels and related indicators for inflammatory myopathy [J]. Laboratory Medicine, 2018, 33(5): 411-415.
[15]	ZHANG Mingxu, DING Xiaoling, LI Lei. Comparison on 25-hydroxyvitamin D levels between pregnant and non-pregnant childbearing age women [J]. Laboratory Medicine, 2017, 32(9): 753-756.